Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Effects of dietary Bacillus coagulans and yeast hydrolysate supplementation on growth performance, immune response and intestinal barrier function in weaned piglets.

  • 2021-03-14
  • Journal of Animal Physiology and Animal Nutrition 105(5)
    • Runqi Fu
    • Chan Liang
    • Daiwen Chen
    • H. Yan
    • G. Tian
    • P. Zheng
    • Jun He
    • Jie Yu
    • X. Mao
    • Zhiqing Huang
    • Yuheng Luo
    • Junqiu Luo
    • B. Yu

Abstract

The present study investigated the effects of Bacillus coagulans and yeast hydrolysate supplementation on growth performance, immune response and intestinal barrier function of weaned piglets. Twenty-four weaned piglets with an average body weight (BW) of 6.89 ± 0.15 kg were divided into four diets for 28 days. The treatments were basal diet (control), basal diet supplemented with antibiotic (20 mg/kg colistin sulphate and 40 mg/kg bacitracin zinc, AT), probiotics (400 mg/kg Bacillus coagulans ≥5 × 109 CFU/g, BC) or yeast hydrolysate (5000 mg/kg yeast hydrolysate, YH). Average daily gain (ADG) and average daily feed intake (ADFI) were improved by AT and YH diets (p < 0.05), while BC diet only increased ADG (p < 0.05). The complement 3 (C3), lysozyme (LZM) and tumour necrosis factor-α (TNF-α) concentrations in serum were increased in BC diet (p < 0.05). Feeding AT and YH caused the increase of jejunal villus height (p < 0.05), and a higher ratio of villus height/crypt depth was observed in AT, BC and YH groups (p < 0.05). The mRNA expression of zonula occludens-1 (ZO-1) in jejunal mucosa was up-regulated by AT, BC and YH diets (p < 0.05). Dietary AT, BC or YH inclusion decreased the interleukin-1β (IL-1β) concentration and TNF-α mRNA expression (p < 0.05), and YH supplementation even down-regulated toll-like receptor 4 (TLR4) and CD14 expressions (p < 0.05). In summary, the dietary administration of BC or YH both improves growth performance through promoting the intestinal barrier function, indicating both of them can serve as potential alternatives to antibiotics growth promoters for the piglet production.

Keywords: Bacillus coagulans; growth performance; immune function; intestinal barrier; weaned piglets; yeast hydrolysate.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bacillus coagulansImproved Average Daily GainBeneficial
Moderate
Bacillus coagulansIncreased Serum Complement 3 (C3) LevelsBeneficial
Moderate
Bacillus coagulansIncreased Serum Lysozyme LevelsBeneficial
Moderate
Bacillus coagulansIncreased Tumor Necrosis Factor-Alpha LevelsBeneficial
Moderate
Bacillus coagulansIncreased Villus Height to Crypt Depth RatioBeneficial
Moderate
Bacillus coagulansIncreased ZO-1 mRNA Expression in Jejunal MucosaBeneficial
Large
Bacillus coagulansReduced Interleukin-1β LevelsBeneficial
Moderate
Bacillus coagulansReduced Tumour Necrosis Factor-α (TNF-α) mRNA ExpressionBeneficial
Moderate
Bacillus coagulans LactoSpore 1 billion CFUImproved Growth PerformanceBeneficial
Moderate
Bacillus coagulans LactoSpore 1 billion CFUImproved Immune ResponseBeneficial
Moderate
Bacillus coagulans LactoSpore 1 billion CFUImproved Intestinal Barrier FunctionBeneficial
Moderate
Bacillus coagulans LactoSpore 1 billion CFUReduced Inflammatory MarkersBeneficial
Moderate
Bacillus coagulans MTCC 5856Improved Growth PerformanceBeneficial
Moderate
Bacillus coagulans MTCC 5856Improved Immune ResponseBeneficial
Moderate
Bacillus coagulans MTCC 5856Improved Intestinal Barrier FunctionBeneficial
Moderate
Bacillus coagulans MTCC 5856Reduced Inflammatory MarkersBeneficial
Moderate
Bacillus coagulans ProDuraImproved Immune ResponseBeneficial
Moderate
Bacillus coagulans ProDuraImproved Intestinal Barrier FunctionBeneficial
Moderate
Bacillus coagulans ProDuraReduced Inflammatory MarkersBeneficial
Moderate
Bacillus coagulans SC208Improved Growth PerformanceBeneficial
Moderate
Bacillus coagulans SC208Improved Immune ResponseBeneficial
Moderate
Bacillus coagulans SC208Improved Intestinal Barrier FunctionBeneficial
Moderate
Bacillus coagulans SC208Reduced Inflammatory ResponseBeneficial
Moderate
Bacillus coagulans SNZ-1969Improved Growth PerformanceBeneficial
Moderate
Bacillus coagulans SNZ-1969Improved Immune ResponseBeneficial
Moderate
Bacillus coagulans SNZ-1969Improved Intestinal Barrier FunctionBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Inflammatory MarkersBeneficial
Moderate
Bacillus coagulans Unique IS-2Increased Average Daily GainBeneficial
Moderate
Bacillus coagulans Unique IS-2Increased Serum Complement 3 (C3) LevelsBeneficial
Moderate
Bacillus coagulans Unique IS-2Increased Serum Lysozyme LevelsBeneficial
Moderate
Bacillus coagulans Unique IS-2Increased Serum Tumor Necrosis Factor-α LevelsNeutral
Small
Bacillus coagulans Unique IS-2Increased Villus Height to Crypt Depth RatioBeneficial
Moderate
Bacillus coagulans Unique IS-2Increased ZO-1 mRNA Expression in Jejunal MucosaBeneficial
Large
Bacillus coagulans Unique IS-2Reduced Interleukin-1β ConcentrationBeneficial
Small
Bacillus coagulans Unique IS-2Reduced TNF-α mRNA ExpressionBeneficial
Small
Back to top